DGIdb 3.0: a redesign and expansion of the drug–gene interaction database

Kelsy C. Cotto^{1,†}, Alex H. Wagner^{1,*,†}, Yang-Yang Feng¹, Susanna Kiwala¹, Adam C. Coffman¹, Gregory Spies¹, Alex Wollam¹, Nicholas C. Spies¹, Obi L. Griffith^{1,2,3,4,*} and Malachi Griffith^{1,2,3,4,*}

¹McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO 63108, USA, ²Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA, ³Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA and ⁴Department of Genetics, Washington University School of Medicine, St Louis, MO 63110, USA

Received September 16, 2017; Revised October 20, 2017; Editorial Decision October 21, 2017; Accepted November 06, 2017

ABSTRACT

The drug-gene interaction database (DGldb, www. dgidb.org) consolidates, organizes and presents drug-gene interactions and gene druggability information from papers, databases and web resources. DGIdb normalizes content from 30 disparate sources and allows for user-friendly advanced browsing, searching and filtering for ease of access through an intuitive web user interface, application programming interface (API) and public cloud-based server image. DGIdb v3.0 represents a major update of the database. Nine of the previously included 24 sources were updated. Six new resources were added, bringing the total number of sources to 30. These updates and additions of sources have cumulatively resulted in 56 309 interaction claims. This has also substantially expanded the comprehensive catalogue of druggable genes and anti-neoplastic drug-gene interactions included in the DGldb. Along with these content updates, v3.0 has received a major overhaul of its codebase, including an updated user interface, preset interaction search filters, consolidation of interaction information into interaction groups, greatly improved search response times and upgrading the underlying web application framework. In addition, the expanded API features new endpoints which allow users to extract more detailed information about queried drugs, genes and drug-gene interactions, including listings of PubMed IDs, interaction type and other interaction metadata.

INTRODUCTION

The drug-gene interaction database (DGIdb, www.dgidb. org) was first released in 2013 to consolidate drug-gene interactions and potentially druggable genes into a single resource with a powerful interface to query these data (1). DGIdb 2.0 was released in 2016 and featured substantial content updates, a more intuitive user interface and the inclusion of an application programming interface (API) (2). Despite the success of the DGIdb, 2.0 became outdated in several ways. New sources have become available since 2.0's release and many existing sources within the database required updates. The notion of grouping drug claims (an assertion of a drug concept by a constituent resource) to match a canonical drug source (PubChem compounds), and grouping gene claims (an assertion of a gene concept by a constituent resource) to a canonical gene source (NCBI Entrez Gene) was described in the 2.0 paper (3,4). In brief, grouping allows the DGIdb to relate disparate representations of a gene or drug concept through a core entity, or group. As the database grew, the grouping success rates dropped and new classes of drugs were not fully represented in the search results. Additionally, while the DGIdb grouped drug and gene claims, interactions were still reported at the claim level, with no concept of interaction groups. Furthermore, the initial API that was released alongside 2.0 had limited endpoints that prevented users from extracting additional information about their queried drug-gene interactions, such as PubMed IDs (PMIDs) supporting the interactions and other interaction metadata. Finally, the DGIdb has grown enormously since its initial publication in 2013, and as a result, interaction searches had become significantly slower. This new release addresses these limitations, providing an improved user interface, quicker response times for searches and new meth-

*To whom correspondence should be addressed. Tel: +1 314 286 1800; Fax: +1 314 286 1810; Email: awagner24@wustl.edu

Correspondence may also be addressed to Obi L. Griffith. Tel: +1 314 747 9248; Fax: +1 314 286 1810; Email: obigriffith@wustl.edu Correspondence may also be addressed to Malachi Griffith. Tel: +1 314 286 1274; Fax: +1 314 286 1810; Email: mgriffit@wustl.edu

[†]These authors contributed equally to the paper as first authors.

© The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

ods for accessing and incorporating the DGIdb into bioinformatics workflows.

EXPANDED CONTENT

For 3.0, there has been a substantial expansion of the content of the database through the addition of new sources and the updating of existing sources. Six new sources have been added, which brings the total number of sources represented by the DGIdb to 30. Three of these new sources provide drug-gene interactions from prominent expert-curated databases of clinically actionable variants similar to the CIViC and Clearity Foundation sources, already included in the DGIdb (Supplementary Table S1) (5). These include the Precision Oncology Knowledge Base (OncoKB), cancer genome interpreter (CGI) and The Jackson Laboratory Clinical Knowledgebase (CKB) (Supplementary Table S1) (6,7). From these three new sources, 2822 new interaction claims were added. These sources were added as anti-neoplastic interaction sources, resulting in an 36.7% increase in anti-neoplastic drugs. Drug-gene interactions were also added from the United States Food and Drug Administration (FDA) Pharmacogenomics website and the National Cancer Institute (NCI) Cancer Gene Index, resulting in an additional 276 and 6231 interaction claims, respectively (Supplementary Table S1). In addition to these sources, the existing druggable gene category sources were expanded with data extracted from a new druggable genome paper that used computational approaches to identify druggable genes from genome-wide association studies (Supplementary Table S2) (8). The inclusion of this source into the DGIdb results in an additional 2300 potentially druggable genes, a 58% increase from 2.0 (Figure 1). Notably, this independent definition of the druggable genome almost completely encapsulates many other gene categories (e.g. kinases, G-protein coupled receptors) that are expected to be good drug targets (Supplementary Figure S1).

As the DGIdb has matured, maintaining current representations of existing sources has become increasingly important relative to identifying new interaction sources. Curated updates of drug-gene interaction data from My Cancer Genome and the targeted and biologic therapies for non-small-cell lung cancer (TALC) have occurred, resulting in moderate increases in drug-gene interactions from these sources (9,10). To help prevent regularly updated sources from becoming outdated in the DGIdb, we have rewritten and expanded online updaters to keep frequently updated sources current within the database. With these more frequent, incremental updates to the DGIdb, there has been a substantial increase in drug-gene interaction content from IUPHAR's Guide to Pharmacology and CIViC, a 23 and 200% increase, respectively (5,11). Additionally, a major update of DrugBank from version 4.3 to 5.0 was performed, resulting in a 30% increase in interaction claims from this source (12). Gene Ontology was also updated which provided a moderate increase for the druggable gene categories (13). For this release, 18 493 new interaction claims were added, of which 50% were from updated sources and 50%from new sources. In total, there are now 6106 druggable genes and 29 783 drug-gene interactions, which cover 41 100 genes and 9495 drugs, within the DGIdb.

The enhancements to the online updaters have also been applied to Entrez Gene, from which 99% of all gene claims made by the DGIdb constituent sources were grouped (Supplementary Figure S2) (3). Another major change from 2.0 to 3.0 is that the canonical drug source for the DGIdb has switched from using PubChem compounds to ChEMBL molecules (14). This switch has added 1.7 million ChEMBL molecules to the database for potential matching to drug claims. Importantly, switching to ChEMBL has added 195 antibody drugs (e.g. trastuzumab, cetuximab), a drug class that is absent from the PubChem database and frequently requested by users. These antibody drugs matched to 539 distinct drug claims from the constituent sources of the DGIdb. With ChEMBL as the canonical drug source and the improvements to the grouping strategy below, 80.2% of all drug claims now group. Many of the resources we pull from strive to be as comprehensive as possible, and sometimes include broad classes of drug or therapy (e.g. 'hormone therapy', 'mtor inhibitors', 'chemotherapy', 'radiation', 'antibiotics', etc.), which account for a large percentage of the remaining drug claims.

NEW FEATURES AND ENHANCEMENTS

A major feature added in 3.0 is a user-selectable series of preset filters. These allow users to select drug-gene interactions that align with some of the most common search use cases. While it was possible for a user to filter on some of the following attributes in 2.0, these concepts have now been structured as stand-alone filters that can help focus a user's search results with a single click. The filters currently include FDA-approved drugs, anti-neoplastic drugs, immunotherapy drugs, clinically actionable genes, genes included in the druggable genome definition and drug resistant genes. FDA approval status is extracted from ChEMBL v23 (current as of this writing) (14). Anti-neoplastic drugs are defined by inclusion in an anti-neoplastic drug-gene interaction source (e.g. My Cancer Genome), or as a drug with an anti-neoplastic attribute from its constituent source. Immunotherapy drugs are defined as any drug with an attribute of 'immunosuppressive agent', 'immunomodulatory agent' or 'immunostimulant'. Clinically actionable genes are genes that constitute the DGIdb 'clinically actionable' gene category, and by definition is used to inform clinical action (e.g. the Foundation One diagnostic gene panels). Similarly, druggable genome genes are genes listed in the DGIdb 'druggable genome' gene category (8,11,13,15–19). Drug resistance genes are defined by the Gene Ontology as genes that confer drug resistance or susceptibility (GO identifier 0042493), and are maintained in the DGIdb through the 'drug resistance' gene category (13). To incorporate these new filters, we have redesigned the data model, expanded the definition of the druggable genome and restructured the user interface (UI) to include a redesigned search form and results interface. The UI also now features drug, gene and interaction views to leverage the new grouping strategies and preset filters.

Since the last release, several changes have been made to the drug grouping strategy to improve overall grouping percentages. We have added support for fuzzy searching when grouping if direct matches to drug groups are not found, en-




Figure 1. DGIdb 3.0 content by source. The number of drug-gene interaction claims (first panel) and druggable gene categories (second panel) are separated into three categories: sources that existed in the DGIdb previously, sources that existed in the DGIdb previously but have been updated for 3.0 or sources that are entirely new to the DGIdb. Abbreviations: CF: Clearity Foundation; CGI = Cancer genome interpreter, CKB = JAX-Clinical Knowledgebase, CMI = Caris Molecular Intelligence, FO = Foundation One, GTP = Guide to pharmacology, MCG = My cancer genome, OncoKB = Precision Oncology Knowledge Base, TALC = Targeted agents in lung cancer, TTD = Therapeutic Target Database, TEND = Trends in the exploration of novel drug targets, GO = Gene Ontology and MSK = Memorial Sloan Kettering.

abling grouping of drug claims with slightly different means of joining multi-word terms (whitespace, dashes and underscores). Code has also been added to identify and remove aliases that are highly ambiguous to improve exact matching of drug claims.

In addition to improved drug grouping, we have added interaction grouping, linking together interaction claims from multiple sources that describe the exact same drug-gene interaction. The grouping efficiency for interactions is 75.2%. The successful grouping of an interaction claim is dependent on the associated gene claims and drug claims successfully grouping. As a result, interaction grouping percentages are closely related to the grouping percentages for drugs and genes (Supplementary Figure S2). The introduction of interaction groups has led to a noticeable improvement in response times on the UI for interaction searches, even when query sizes and result sizes grow larger (Figure 2). Before interaction groups were created, searches in 2.0 had to query almost twice as many database tables as in 3.0. Interaction groups allow for more efficient queries, which leads to a 14-fold reduction in response times when searching the DGIdb.

We have expanded and added additional API endpoints that now allow users to extract more information on the drug-gene interactions provided by the DGIdb. These include endpoints to list all the interaction groups, gene groups and drug groups in the DGIdb, as well as endpoints to view detailed information about an individual interaction, gene or drug group. Drug/gene/interaction group endpoints include various metadata about the group including its constituent claims. The information presented in the interaction search results endpoint has been expanded to include the Entrez and Chembl ID of the gene and drug involved in an interaction, as well as a list of publications that support each interaction search through the API. This brings the interaction search endpoint in sync with the user interface. Moreover, the information presented in the interaction search results and the new individual endpoints for interactions, genes and drugs more closely mirrors the views available via the user interface. These new endpoints allow users to more efficiently export all of the data available in the DGIdb.

USER INTERFACE (UI) UPDATES

The 3.0 release of the DGIdb features a dramatic overhaul of the UI that reflects many of the backend changes detailed above. The search interactions page now allows the user to apply the new preset filters in addition to the existing advanced filters (e.g. source databases, gene categories and interaction types) directly on the search form (Figure 3). On performing a search, the user is redirected to the redesigned search interactions results page, enabled by a new concept of interaction groups instead of individual interaction claims. This new view displays search results as lists of visually distinct panels for each search term mapped to gene or drug groups. A list of uniquely matched terms is shown in one tab whereas a second tab summarizes the list of ambiguously matched search terms and unmatched terms. Each panel displays a table of interaction groups, along with summaries of the respective interaction types, sources, supporting publication PMIDs and a ranking. Users interested in a particular interaction can navigate from the interaction search results to the corresponding interaction group view. Similarly, detailed information about an interacting gene or drug can be found in the associated gene or drug group view (Supplementary Figure S3). These new group views feature (i) a summary tab, which details all relevant information collected from the various source claims (e.g. aliases, FDA approval status, supporting publications); (ii) an interactions tab (for gene and drug group views), which lists summary panels of each interaction in the DGIdb for this gene or




Figure 2. Comparison of the DGIdb 2.0 and 3.0 response time by search and result size. The left panel summarizes observed response times (n = 100) for searches of various sizes (1, 2, 3, 4, 5, 10, 15, 20 and 25) of randomly selected genes. The right panel summarizes observed response times for the corresponding interaction search result sizes.

drug; and (iii) a *claims tab* with detailed information about each claim supporting the group.

USAGE AND ACCESSIBILITY

The utility of the DGIdb as a resource is reflected in its substantial web and especially API traffic. The website receives \sim 1700 unique users and \sim 2800 sessions a month, an increase of 42 and 39%, respectively, since the initial release of the DGIdb. Additionally, 42% of unique visitors within the past year were returning users. Within the last year, the DGIdb API has been used by 3689 unique IP addresses for a total of 939 429 requests, as seen in Supplementary Figure S4. At the time of publication, 2.0 was used by a number of bioinformatics tools in the development of their platforms. DGIdb has since been integrated into four additional tools, bringing the total number of known platforms that utilize the DGIdb to 10. These platforms are GeneCards (http: //www.genecards.org), CVE (20), rDGIdb (21), PANDA (22), iCAGES (icages.usc.edu), BioGPS (23), Omics Pipe (24), GEMINI (25), StationX (www.stationxinc.com) and IHLDB.rf (www.lungcancerdatabase.com). These integrations highlight the accessibility and utility of the DGIdb API, which has been expanded to include new endpoints in 3.0.

To handle the increasing usage of the DGIdb, the database backend has undergone significant updates. One of the most notable is the upgrade from Rails 3 to the Rails 5 framework. We also added 22 new tables to the PostgreSQL database schema consisting of 2 326 676 records supporting the described changes and added 4065 new lines of code to the repository, an expansion of the codebase by 18.9%. This activity can be seen through the commit history to the GitHub repository in Supplementary Figure S5. For access to this code and data, please see the availability section below.

The open source DGIdb software was previously available under the GNU General Public License 3.0 (GPL3) and has been re-released under the more permissive MIT license. The data contained within the DGIdb are available under the licenses assigned by their host sources which makes it possible to integrate the DGIdb into any workflow. Since 2.0, the database has moved from being hosted on a local server to being hosted on Amazon Web Services. With this change in server host, the availability of the DGIdb has been expanded through the release of two Amazon Machine Images, a development environment and production environment. By providing this production environment for users, we now support a quick-start solution for private, cloud-based applications.

CONCLUSION AND FUTURE DIRECTIONS

DGIdb 3.0 has undergone significant changes. The number of drug-gene interactions and druggable genome definitions has been substantially expanded through the updating of existing sources and inclusion of new sources. To improve searches, we have included preset filters that allow searches for commonly requested gene or drug classes. To utilize these filters, a more intuitive UI was created and new fields to the database schema were added. Additionally, there are new ways to both access the data within the DGIdb and to deploy local or cloud instances of the database.

While the DGIdb remains a powerful resource for querying drug-gene interactions, we anticipate future changes that will improve the user experience and the content within it. One change is that claim information will be linked to the licensing terms from constituent sources through the various methods of accessing the DGIdb including the web interface, API endpoints and data downloads. Second, while grouping statistics for claims have improved in the DGIdb 3.0, there are still a significant percentage of claims that remain ungrouped. To address this, the drug grouper will need to be optimized to handle the exceptions that currently prevent successful grouping. Third, much of the user interface is a series of static renders by the server. A potential future enhancement is a more reactive, client-side web application that would allow for more dynamic visualization and exploration of the data. Finally, other databases (e.g. CIViC)

Unity miniferations Primus Source MIDOSTAURIN inhibitor MyGancerdamma 164/2010/2011/02/2011/0									
Genes Drugs FDA Approved Antimeoplastic Immunotherapies Filer the DRUGS that interact with your GENES Filer the DRUGS that interact with your GENES Clear Identifier Replace with Demo List Second Terr: FLT Clear Identifier FLT Very Were Ferset						A Pre	eset Filters 🛽 🖪		
		Ger	nes	Dr	rugs		•		
						Filte	er the DRUGS tha	t interact	with your GENES
						Adv	vanced Filters	3	
						So	urce Databases		
						20	0 of 20 \$		
					//				
	C	lear Iden	ntifiers	Replace with	n Demo List				
Search Term: "FLT1" FLT1 FLT1 Drug Interaction Sources PMIDs Score SUMTINE Inibian Table Table Score SUMTINE Inibian Table Table Score Preset Filters SUMTINE Inibian Table Table Score Preset Filters SUMTINE Inibian Table Score Table Table Preset Filters Statut Table Table Score Table Table Preset Filters Statut Table Table Score Table Table Preset Filters Statut Table Table Score Table Table Table Table Table Table <th></th> <th></th> <th></th> <th>C</th> <th>2 Find Dru</th> <th>ug-Gene In</th> <th>teractions</th> <th></th> <th></th>				C	2 Find Dru	ug-Gene In	teractions		
Search Term: "FLT1" FLT1 FLT1 Drug Interaction Sources PMIDs Score SUMTINE Inibian Table Table Score SUMTINE Inibian Table Table Score Preset Filters SUMTINE Inibian Table Table Score Preset Filters SUMTINE Inibian Table Score Table Table Preset Filters Statut Table Table Score Table Table Preset Filters Statut Table Table Score Table Table Preset Filters Statut Table Table Score Table Table Table Table Table Table <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
Search Term: "FLT1" FLT1 FLT1 Drug Interaction Sources Philos Score Sype Total Contraction Sources Philos Score Sype Total Contraction Sources Philos Score Sype Total Contraction Sources Philos Score Statistics Total Contraction Sources Philos Score Statistics Total Contraction Sources Philos Score Statistics Total Contraction Source Contraction Source Contraction Total Contraction Statistics Total Contraction Source Contraction Source Contraction Total Contraction Total Contraction Source Contraction Total Contraction Source Contraction Total Contraction Total Contraction Total Contraction Source Contraction Total Contraction Source Contraction Total Contraction		•							
Search Term: "FLT1" FLT1 FLT1 Drug Interaction Sources Philos Score Sype Total Contraction Sources Philos Score Sype Total Contraction Sources Philos Score Sype Total Contraction Sources Philos Score Statistics Total Contraction Sources Philos Score Statistics Total Contraction Sources Philos Score Statistics Total Contraction Source Contraction Source Contraction Total Contraction Statistics Total Contraction Source Contraction Source Contraction Total Contraction Total Contraction Source Contraction Total Contraction Source Contraction Total Contraction Total Contraction Total Contraction Source Contraction Total Contraction Source Contraction Total Contraction	Matahaa	U	Lomoto	* - a					
Search Term: "FLIT" FLIT" FLIT Drug Interaction Sources Type PMIDs Score Type SUNTINE inhibitor TAD Spacestamment Spacestam	ique Matorioo	Anioigu	OUS OF UTITIALS	hed					
Pring Interaction Sources Print Sources SUMTINE Inhibitor EXX1 Exignmention (CD E									A contract of the second se
SXITINB inhibitor Concentration	Searc	ch Term:	"FLT1"	FLT1					Download as TSV
Control Contro <thcontrol< th=""> <thcontrol< th=""> <thco< td=""><td>_</td><td>Interaction</td><td></td><td>▶ <u>FLT1</u></td><td></td><td></td><td>PMIDs</td><td>Score</td><td></td></thco<></thcontrol<></thcontrol<>	_	Interaction		▶ <u>FLT1</u>			PMIDs	Score	
SCAVE PLNE Initialized States Fundamental Sta	Drug	Interaction Type	Sources		DrugBank MyCancerG	enomeGlinicalTrial	21478036 17367763		Preset Filters Unique
Inhibitor CoupSerSemanassesseyutinezatures Surgedee PA2COPANUE Inhibitor Citics Semanassesseyutinezatures Danassesseyutinezatures 7 TVO22ANIE Inhibitor Citics Semanassesseyutinezatures Citics Semanassesseyutinezatures None found 7 VX1ALANIE Inhibitor Citics Semanassesseyutinezatures Citics Semanassesseyutinez	Drug SUNITINIB	Interaction Type inhibitor	Sources TALC TdgClin TALC Pharm0	nicalTrial CGI TEND	TdgClinicalTrial Chen		21478036 17367763 24086736 14654525	10	Preset Filters Unique Matches @ Search Term: FLT1
Mycaneerdenous: Mycaneerdenous: Topologinestituitie Ceaserdenous: Ceaserde	Drug SUNITINIB AXITINIB SORAFENIB	Interaction Type inhibitor inhibitor inhibitor	Sources TALC TdgClin TALC Pharmo CancerCommon	nicalTrial CGI TEND GKB MyCancerGenome ns MyCancerGenomeCili) TdgClinicalTrial Chem InicalTrial	mblinteractions DrugBank	21478036 17367763 24086738 14654525 18541897 17016424 15466206 16507829	10 9 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
Claight Selection Survey Selection State Selecion State Selection State Selection State Selection State Selecti	Drug SUNITINIB AXITINIB SORAFENIB	Interaction Type inhibitor inhibitor inhibitor inhibitor,	Sources TALC TdgClin TALC Pharmo CancerCommor MyCancerGenoor	nicaTrial CGi TEND GKB MyCancerGenome ms MyCancerGenomeCili me DrugBank MyCan cerGenome TdgClinicaT	TdgClinicalTrial Cher inicalTrial ncerGenomeClinicalTrial Trial ClearityFoundation	mblinteractions CrugBank	21478036 17367763 24086738 14654525 18541897 17016424 15466206 16507829	10 9 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
CEDIRANIE Inhibitor TALE Tageina CEDIRANIE Inhibitor TALE Tageina CountyFoundationaditionality all (CountyFoundationaditionality all (CountyFoundationadity all (CountyFoun	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB	Interaction Type inhibitor inhibitor inhibitor inhibitor, inhibitor	Sources TALC TdgClir TALC Pharmo CancerCommor MyCancerCenol TALC MyCan MyCancerGenol TALC MyCan	HealTrial GGI TEND AKU MyCancerGenomeCli MyCancerGenomeCli MyCancerGenomeCli GrugBark MyCancer Geogenetrations CerGenom TegClinical CerGenom TegClinical mecCincelTrial	TdgClinicaTfrial CheminicalTfrial inicalTfrial	mbilinteractions DrugBank TTD ClinicsTrial opyInteractions DrugBank	21476056 17587763 3468756 14654525 18541897 17016424 15666206 16507625 18559524	10 9 7 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
Indue Matches Ambiguous or Unmatched E Search Term: "STK1" FLT3 Drug Interaction Sources Type PMIDs Score MIDOSTAURIN Inhibitor Medicedemantalian Grading Training 1788/720 1986/710 2004/812	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB	Interaction Type inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC Tdyclin TALC Pharma CancerCommon MyCancerGeno TALC MyCan MyCancerGeno TALC MyCan MyCancerGeno TALC MyCan GuidoToPharma	nicerfrael CGI TEND CKD MyCancerGenome ns Un/CancerGenomeCD MyCancerGenomeCD TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical cerGenome TdyClinical	Tdg/ElinicalTrial Chem Instantial Chem near/Genome/ClinicalTrial Instantial Trial Clearlyf-sundation Blank Clearlyf-sundation Trial Clearlyf-sundation Trial Clearlyf-sundation	ITTD ClinicalTrial Commons	21476056 17587763 2468756 14664525 18541807 1566206 16507820 1566206 16507820 1558563 1728876 None found	10 9 7 7 7 7 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
Search Term: "STK1" ▶ FLT3 Drug Interaction Sources Type PMIDs Score MIDOSTAURIN Inhibitor MCCreatedenome 160/Clineating Code 1788/701 2658/705 1658/705 1788/705 1588/7	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB	Interaction Type inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC Togelit TALC Phann Calcel Commen Calcel Commen TALC MyCancerGeno TALC MyCan TALC MyCan TALC MyCan TALC MyCan TALC MyCan TALC MyCan	Healfinial CGI TEND DKE MyGancerGenome DyGancerGenomeCil me DrugBank MyGan congenerations TogGlinicat meCiliciatTital serGenome TogGlinicat	Tdg/ElinicalTrial Chem Instantial Chem near/Genome/ClinicalTrial Instantial Trial Clearlyf-sundation Blank Clearlyf-sundation Trial Clearlyf-sundation Trial Clearlyf-sundation Trial Clearlyf-sundation	ITTD ClinicalTrial Commons	21476056 17587763 2468756 14664525 18541807 1566206 16507820 1566206 16507820 1558563 1728876 None found	10 9 7 7 7 7 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
Search Ierm: "STK1" FLI3 Unmatched Terms Type Interaction Type Null Mccaecedenome Topoliticalities Topoliticalities Topoliticalities Score MIDOSTAURIN Inhibitor McCaecedenome Topoliticalities Topoliti	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB TIVOZANIB TIVOZANIB CEDIRANIB	Interaction Type inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC Togelin TALC Phann Calcel Commer Calcel Commer TALC MyCancerGenol TALC MyCan TALC MyCan TALC MyCan TALC MyCan TALC MyCan TALC MyCan TALC MyCan TALC MyCan	NGLITILIA CGI TEND GATO MyGancerGenomeCi MyGancerGenomeCi DrugBank MyGan cerGenome Tedgelinicati cerGenome Tedgelinicati meclinicatificati cerGenome Tedgelinicati meclinicatificati cerGenome Tedgelinicati tent ProgBank	Togolinikarfrail Chem micarfrail Trial Cleaning-ClinikarTrial Trial Cleaning-Foundation Blank Trial Cleaning-Foundation Trial Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation	mbilinteractions DrugBank TTD ClinicalTrial ogyInteractions DrugBank ClinicalTrial ClinicalTrial ClinicalTrial Commons	21478056 17587763 2408775 14654525 18541997 17016424 1546525 17016424 1546520 1855523 1855523 19258870 17258870 None found 17584517	10 9 7 7 7 7 7 7 7 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
Interaction Sources PMIDs Score MIDOSTAURIN Inhibitor Mycencerdenome 166/clineatting 1709720 18067101 6057065 15067105 25050214 41 MIDOSTAURIN Inhibitor Mycencerdenome 166/clineatting 1709720 18067101 6057065 15067105 25050214 41 SCRAFENIB antagonis, inhibitor Mycencerdenome 166/clineatting 1709720 18067101 2200105 2200105 25050214 41 SCRAFENIB antagonis, inhibitor Mycencerdenome 166/clineatting 1709720 18067101 1200007 2200105 22000001 309 DUZARTINIB inhibitor Mycencerdenome 166/clineatting 1709720 18067101 1200001 2200105 22000001 309 DUZARTINIB inhibitor Mycencerdenome 166/clineatting 1709720 18067101 1200001 2200105 2200002 22000001 309 DUZARTINIB inhibitor Mycencerdenome 166/clineatting 1709720 18067101 12000012 22000002 22000020 305 <td>Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB TIVOZANIB TIVOZANIB CEDIRANIB</td> <td>Interaction Type inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor</td> <td>Sources TALC TdgCiir TALC Pharmo CenecCommo MyCancerGeno TALC MyCan MyCancerGeno TALC MyCan MyCancerGeno TALC MyCan TALC MYCAN</td> <td>Neutrinia CGI TEND DXE MyGancerGenomeCi me DrugBank MyGan corgenome Telgolinicat corgenome Telgolinicat meCinacatriat corgoniteracions Cent meCinacatriat corgoniteracions Cent corgoniteracions Cent</td> <td>Togolinikarfrail Chem micarfrail Trial Cleaning-ClinikarTrial Trial Cleaning-Foundation Blank Trial Cleaning-Foundation Trial Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation</td> <td>mbilinteractions DrugBank TTD ClinicalTrial ogyInteractions DrugBank ClinicalTrial ClinicalTrial ClinicalTrial Commons</td> <td>21478056 17587763 2408775 14654525 18541997 17016424 1546525 17016424 1546520 1855523 1855523 19258870 17258870 None found 17584517</td> <td>10 9 7 7 7 7 7 7 7 7</td> <td>Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3</td>	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB TIVOZANIB TIVOZANIB CEDIRANIB	Interaction Type inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC TdgCiir TALC Pharmo CenecCommo MyCancerGeno TALC MyCan MyCancerGeno TALC MyCan MyCancerGeno TALC MyCan TALC MYCAN	Neutrinia CGI TEND DXE MyGancerGenomeCi me DrugBank MyGan corgenome Telgolinicat corgenome Telgolinicat meCinacatriat corgoniteracions Cent meCinacatriat corgoniteracions Cent corgoniteracions Cent	Togolinikarfrail Chem micarfrail Trial Cleaning-ClinikarTrial Trial Cleaning-Foundation Blank Trial Cleaning-Foundation Trial Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation	mbilinteractions DrugBank TTD ClinicalTrial ogyInteractions DrugBank ClinicalTrial ClinicalTrial ClinicalTrial Commons	21478056 17587763 2408775 14654525 18541997 17016424 1546525 17016424 1546520 1855523 1855523 19258870 17258870 None found 17584517	10 9 7 7 7 7 7 7 7 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3
MIDOSTAURIN IMIDOSTAURIN INIDIOR DOCM MyGeneerdeeveen GuideThiPharmacology/Marketions CoCM 1788/720 (1986/710) 1986/710) 2620/201 (2920/102) 2920/102) 2920/102) 2920/102) 2920/102) 41 (1) SOCRAFENIB Inihibitor Anto Coc Coc Coc <td>Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB CEDIRANIB Ique Matches</td> <td>Intraction inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor</td> <td>Sources TALC TdgClie TALC TdgClie TALC Pharm CanserComment MyCancerComment MyCancerComment TALC MyCancerComment TALC MyCance</td> <td>sicarinal GGI TEND ACID MyCancerGenome me DrugBank MyCan eerGenome TelgChineat sologyInteractions Drug eerGenome TelgChineat meCinicatiful telgCanter telgCanter TelgCinicat cergenome TelgChineat eerGenome TelgChineat meCinicatiful telgCanter te</td> <td>Togolinikarfrail Chem micarfrail Trial Cleaning-ClinikarTrial Trial Cleaning-Foundation Blank Trial Cleaning-Foundation Trial Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation</td> <td>mbilinteractions DrugBank TTD ClinicalTrial ogyInteractions DrugBank ClinicalTrial ClinicalTrial ClinicalTrial Commons</td> <td>21478056 17587763 2408775 14654525 18541997 17016424 1546525 17016424 1546520 1855523 1855523 19258870 17258870 None found 17584517</td> <td>10 9 7 7 7 7 7 7 7 7</td> <td>Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3 Search Term: AQP9</td>	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB CEDIRANIB Ique Matches	Intraction inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC TdgClie TALC TdgClie TALC Pharm CanserComment MyCancerComment MyCancerComment TALC MyCancerComment TALC MyCance	sicarinal GGI TEND ACID MyCancerGenome me DrugBank MyCan eerGenome TelgChineat sologyInteractions Drug eerGenome TelgChineat meCinicatiful telgCanter telgCanter TelgCinicat cergenome TelgChineat eerGenome TelgChineat meCinicatiful telgCanter te	Togolinikarfrail Chem micarfrail Trial Cleaning-ClinikarTrial Trial Cleaning-Foundation Blank Trial Cleaning-Foundation Trial Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation Cleaning-Coundation	mbilinteractions DrugBank TTD ClinicalTrial ogyInteractions DrugBank ClinicalTrial ClinicalTrial ClinicalTrial Commons	21478056 17587763 2408775 14654525 18541997 17016424 1546525 17016424 1546520 1855523 1855523 19258870 17258870 None found 17584517	10 9 7 7 7 7 7 7 7 7	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3 Search Term: AQP9
CX3 504007C 10524020 27703370 20581050 20641114 20541614 12124177 Guida Forhammaccing infermance COC COC 20201000 20201000 20201000 10540007 1054007 1050007 2020000 2004010 1057007 1054007 1050007 2020000 2004010 1057007 1056007 2004000 2004000 20040000 20040000 200	AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB CEDIRANIB CEDIRANIB	Inhibitor Inhibi	Sources TALC TdgClif TALC TdgClif TALC Pharm CanserCommer MyCancerCent TALC MyCan Caudio TaPharma TALC MyCan Caudio TaPharma TALC MyCan Caudio TaPharma TALC MyCan Chambinessest TALC TdgClif TALC Td	sicarinal GGI TEND ACID MyCancerGenome me DrugBank MyCan eerGenome TelgChineat sologyInteractions Drug eerGenome TelgChineat meCinicatiful telgCanter telgCanter TelgCinicat cergenome TelgChineat eerGenome TelgChineat meCinicatiful telgCanter te	Togolinicatificial Cherr encartinal concerdenomeCollinicatificial ClearlyFoundation Game ClearlyFoundation ClearlyFoundation ClearlyFoundation ClearlyFoundation ClearlyFoundation ClearlyFoundation ClearlyFoundation ClearlyFoundation ClearlyFoundation	mbilinteractions DrugBank TTD ClinicalTrial ogyInteractions DrugBank ClinicalTrial ClinicalTrial ClinicalTrial Commons	21478056 17587763 2408775 14654525 18541997 17016424 1546525 17016424 1546520 1855523 1855523 19258870 17258870 None found 17584517	10 9 7 7 7 7 7 7 7 5	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: ADP9
MyCancer Genome Clinical Trial FDA AUR/S Concert Genome Clinical Trial Concert Genome Trial Genome Clinical Trial Concert Genome Trial Trial Concert Genome Trial Tri	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS	inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC TdgClif Calcerton MyCancerConne Calcerton MyCancerConne Calcerton MyCancerConne Calcerton MyCancerConne Calcerton MyCancerConne Calcerton MyCancerConne Calcerton MyCancerConne MyCancerCon	Acatina Gai TENO AKI MyCancerdenomedi me DrugBark MyCan eerdenom Téglinicat eerdenom Téglinicat medinicatria eerdenom Téglinicat eerdenom Téglinicat medinicatria toologinteration Téglinicat toologinteration toologint	P 1549ClinicalTrial Cher encartrial meartrial meardemensClinicalTrial (ClearlyFoundation mediatriactions) Cancer Trial ClearlyFoundation mediatriactions) Cancer Trial ClearlyFoundation	nblinteractions DrugBank TTD ClinicaTrial ClinicaTrial ClinicaTrial ClinicaTrial ClinicaTrial ClinicaTrial Commons ClinicaTrial Commons ClinicaTrial Commons ClinicaTrial Commons ClinicaTrial ClinicaT	21478056 1789703 2408755 14664555 15541997 17076424 1546206 16007829 1559923 1559923 None found 17286517 None found	10 9 7 7 7 7 7 7 7 7 7 7 7 5 5	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: AQP9 Commond as TSV Unmatched Terms LOC100508755
SORAFENIB antagonist, inhibitor TALCI Togotinicatifuitii OnesoR8 T788/710 T286050 T0051100 24040014 39	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS	inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC TdgClir TALC Pharmin TALC Pharmin TALC MyCancerGeno MyCancerGeno TALC MyCan	searTrial (GI) TENC ACD MyCancerGenome and DyCancerGenome and DyCancerGenome ToyCancerGenome ToyCancerGenome ToyCancer Comparison ToyCancer ToyCa	TdgClinicaThail Cher wicaThail norac/AnomaClinicaThail (Tria: ClearbyFoundation gears) Tria: ClearbyFoundation mainteractions, Cancer Tria: CludeToFharmacek ator:ClinicaThail CludeTyF PMIDs 1760720 1967110 2200270 1967110 2200270 19723134	mbilinteractions DrugBank TTD ClinicaTrial Commons Commons aPharmacology/nteractions aPharmacology/nteractions 228272070 16857085 17 27753394 23391082 29 2220414 22204182 24 22204182 24 22304182 24 23304182 24 23404182 24 23404184 23404184 23404184	1120700 1120700 26080780 14654505 16541977 14654505 1016462 1565020 1016462 1565020 10208570 1566020 10208570 1566020 10208570 1566020 10208570 1566020 10208570 15650216 10208570 15550216 10208570 15550216 10208570 15550216 10208570 15550216 10208570 15550216 102086740 15550216 102086740 12550216 102086740 12550216	10 9 7 7 7 7 7 7 7 7 7 7 7 5 5	Preset Filters Unique Matches Search Term: FLT Search Term: FLT Search Term: AQP9 ADP Download as TSV Unmatched Terms LOC100308755 E FAKE1 Full Full Full Full Full Full Full Ful
GuideBriPharmacology/elterations 233/23/25 1120/068 2204185 2214533 2205270 2073134 C CK7 NO. CVIC TEND DrugBank 25157968 1566000 2261592 14004974 17606455 22504153 23321527 MM1 DOCM TIST/478 1574788 17041750 24400194 1526420 35 0 PLXNB2 QUIZARTINUB inhibitor MyCancerGenorm 1626/201331 2400196 27091471 2605080 2305260 1120006 2305260 7 PFDN5 GuideTbPharmacology/reference 2204181 2204180 22019187 2460190 2305260 1120006 2305260 7 PFDN5	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS IQUE MATCHOS	inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor	Sources TALC TdgClif TALC TdgCl	searina Gai TENO AKI MyCancerdenomedi Sydaneerdenomedi erdenom Tégetineat erdenom Tégetineat erdenom Tégetineat materineatria erdenom Tégetineat materineatria erdenom Tégetineat materineatria erdenom Tégetineat materineatria erdenom Tégetineat erdenome Tégetineatria erdenome tegetineatria erdenome tegetineatria erdenome tegetineatria erdenome tegetineatria erdenome tegetineatria erdenome tegetineatria erdenome tegetineatria erdenome tegetineatria	TdgClinicalTrial Cher encaTrial Cherty/Soundation Glastly/Soundation Glas	mbilinteractions DrugBank TTD ClinicaTrial Commons Commons aPharmacology/nteractions aPharmacology/nteractions 228272070 16857085 17 27753394 23391082 29 2220414 22204182 24 22204182 24 22304182 24 23304182 24 23404182 24 23404184 23404184 23404184	1120700 1120700 26080780 14654505 16541977 14654505 1016462 1565020 1016462 1565020 10208570 1566020 10208570 1566020 10208570 1566020 10208570 1566020 10208570 15650216 10208570 15550216 10208570 15550216 10208570 15550216 10208570 15550216 10208570 15550216 102086740 15550216 102086740 12550216 102086740 12550216	10 9 7 7 7 7 7 7 7 7 7 7 7 5 5	Preset Filters Unique Matches Search Term: FLT Search Term: FLT Search Term: AQP9 ▲ Download as TSV Unmatched Terms LOC100508755 FAKE1 Multiple Matches
DVCM 1557/4780 1557/4780 1567/4780 1700/1700 100	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES	Inhibitor Inhibi	Sources TALC TdgClil TALC TdgCl	searina Coi TENO AKI MyCancerGenomeCi aki MyCancerGenomeCi agenta MyCancerGenomeCi accopyInteractions TogCinear accordination	1 TdgClinicaTrial Cherring sincarTrial secerGenomeClinicaTrial International strict Cleartyf-sundation gBank Trial Cleartyf-sundation gBank Trial GuideToPharmacold Ganeer Trial GuideToPharmacold Ganeer Trial GuideToPharmacold Ganeer Trial GuideToPharmacold GuideToPharmacold PMLDs Statistical Trial GuideToTi 2300250 11100008 2200250 2204270 2023154 3321207 17800720 10657110 1200008 22004181 3321207 1120008	mbilinteractions DrugBanki TTD ClinicalTrial ClinicalTrial ClinicalTrial ClinicalTrial Commons opyInteractions ClinicalTrial Clinical	24470000 1700700 24600700 14654505 24600700 14654505 10014024 15465000 10014024 15465000 10015000 15555000 10016024 15465000 10016024 15455000 10016024 15455000 10016024 15455000 10016024 15455000 10016024 15455000 10016024 15555000 10016024 15555000 10016024 1555500 10016024 15555000 10016024 15555000 10016024 15555000 10016024 1606023 10016024 1606023 10016024 1606023 10016024 16060020 10016024 16060020 10016024 16060020 10016024 16060020 10016024 16060020 10016024 16060020 10016024 16060020 10016024 16060020	10 9 7 7 7 7 7 7 7 7 7 7 7 7 5 5	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT3 Search Term: AQP9 ▲ Download as TSV Unmatched Terms LOC:00508755 FAKE1 Multiple Matches Search AURKB
QUIZARTINIB inhibitor MyGaneerGenome T69/GinearTail T780720 1980710 1680786 11201720 2430010 2430010 12504010 35 CKB 22773384 24002404 2302080 2309286 135066 21999147 5692689 2392928 135066 2199147 2692689 2392928 135066 2199147 2001101 22041101 2004101 2014104	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES	Inhibitor Inhibi	Sources TALC TdgClil TALC TdgCl	Healfrid CG TEND	1 TdgClinicaTrial Cherr sincarTrial sincarTrial SincarTrial Cleartyfoundation Quints Trial GuideToPharmacol Quints Trial GuideToPharmacol Cleartyfoundation MolideToPharmacol Cleartyfoundation MolideToPharmacol Cleartyfoundation MolideToPharmacol Cleartyfoundation Clearty	hbilinteractions DrugBanki TTD ClinicaTrial cognitieractions DrugBanki ClinicaTrial commons Pharmacology/nteractions Pharmacology/nteractions Pharmacology/nteractions 122627070 16857085 17 12775334 2326108 29 2526118 2230188 21 1537480 2327610 16 15374807 16 15374807 16 12276334 1722032 16 12276334 1722032 16	1170000 1708700 24000700 14654505 36000700 14654505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 1566505 100000 2050000 100000 2056000 1000000 1565505 1000000 1565505 1000000 1565505 10000000 1565505 100000000 1565505 1000000000000000000000000000000000000	10 9 7 7 7 7 7 7 7 7 7 7 7 7 5 5	Preset Filters Unique Matches Search Term: FLT1 Search Term: FLT2 Search Term: FLT2 Search Term: AQP9 Download as TSV Unmatched Terms LOC100508755 FAKE1 UNItiple Matches STK1 CAURKB FFLT3
Ch3 Zariossan Zerossan Zerossan <thzerossan< th=""> Zerossan <thz< td=""><td>Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES</td><td>Inhibitor Inhibitor Inhibi</td><td>Sources TALC TrágClin TALC Trá</td><td>Healfrid CG TEND</td><td>1 TdgClinicalTitali Cherrison InserceConserceClinicalTitali InserceConserceClinicalTitali InserceConserceClinicalTitali Trial CliasthyFoundations Cancert Trial GuideToFharmaced InserceConserceClinicalTitali InserceConserceClinicalTitali GuideToFharmaced GuideToFharmaced Cancert Trial GuideToFharmaced GuideToFharmaced PMIDs InserceClinicalTitali GuideToFharmaced 2000205 InserceClinicalTitali GuideToFharmaced 2010205 InserceClinicalTitali GuideToFharmaced <td< td=""><td>hbilinteractions DrugBanki TTD ClinicaTrial cognitieractions DrugBanki ClinicaTrial commons Pharmacology/nteractions Pharmacology/nteractions Pharmacology/nteractions 122627070 16857085 17 12775334 2326108 29 2526118 2230188 21 1537480 2327610 16 15374807 16 15374807 16 12276334 1722032 16 12276334 1722032 16</td><td>1170000 1708700 24000700 14654505 36000700 14654505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 1566505 100000 2050000 100000 2056000 1000000 1565505 1000000 1565505 1000000 1565505 10000000 1565505 100000000 1565505 1000000000000000000000000000000000000</td><td>10 9 7 7 7 7 7 7 7 7 7 7 7 7 5 5</td><td>Preset Filters Unique Matches Search Term: FL11 Search Term: FL12 Search Term: AQP9 Download as TSV Unmatched Terms LOC100508755 FAKE1 Multiple Matches STK1 CH13 CDK7 CMM1</td></td<></td></thz<></thzerossan<>	Drug SUNITINIB AXITINIB SORAFENIB NINTEDANIB PAZOPANIB TIVOZANIB IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES IQUE MATCHES	Inhibitor Inhibi	Sources TALC TrágClin TALC Trá	Healfrid CG TEND	1 TdgClinicalTitali Cherrison InserceConserceClinicalTitali InserceConserceClinicalTitali InserceConserceClinicalTitali Trial CliasthyFoundations Cancert Trial GuideToFharmaced InserceConserceClinicalTitali InserceConserceClinicalTitali GuideToFharmaced GuideToFharmaced Cancert Trial GuideToFharmaced GuideToFharmaced PMIDs InserceClinicalTitali GuideToFharmaced 2000205 InserceClinicalTitali GuideToFharmaced 2010205 InserceClinicalTitali GuideToFharmaced <td< td=""><td>hbilinteractions DrugBanki TTD ClinicaTrial cognitieractions DrugBanki ClinicaTrial commons Pharmacology/nteractions Pharmacology/nteractions Pharmacology/nteractions 122627070 16857085 17 12775334 2326108 29 2526118 2230188 21 1537480 2327610 16 15374807 16 15374807 16 12276334 1722032 16 12276334 1722032 16</td><td>1170000 1708700 24000700 14654505 36000700 14654505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 1566505 100000 2050000 100000 2056000 1000000 1565505 1000000 1565505 1000000 1565505 10000000 1565505 100000000 1565505 1000000000000000000000000000000000000</td><td>10 9 7 7 7 7 7 7 7 7 7 7 7 7 5 5</td><td>Preset Filters Unique Matches Search Term: FL11 Search Term: FL12 Search Term: AQP9 Download as TSV Unmatched Terms LOC100508755 FAKE1 Multiple Matches STK1 CH13 CDK7 CMM1</td></td<>	hbilinteractions DrugBanki TTD ClinicaTrial cognitieractions DrugBanki ClinicaTrial commons Pharmacology/nteractions Pharmacology/nteractions Pharmacology/nteractions 122627070 16857085 17 12775334 2326108 29 2526118 2230188 21 1537480 2327610 16 15374807 16 15374807 16 12276334 1722032 16 12276334 1722032 16	1170000 1708700 24000700 14654505 36000700 14654505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 15664505 100000 1566505 100000 2050000 100000 2056000 1000000 1565505 1000000 1565505 1000000 1565505 10000000 1565505 100000000 1565505 1000000000000000000000000000000000000	10 9 7 7 7 7 7 7 7 7 7 7 7 7 5 5	Preset Filters Unique Matches Search Term: FL11 Search Term: FL12 Search Term: AQP9 Download as TSV Unmatched Terms LOC100508755 FAKE1 Multiple Matches STK1 CH13 CDK7 CMM1
Chemblinteractions CGI CIVIC 23878140 14604974 17606455 22504183 23321257 15374878	Drug SUNITINIB SORAFENIB NINTEDANIB PAZOPANIB PAZOPANIB TIVOZANIB VATALANIB CEDIRANIB CEDIRANIB IQUE Matches IQUE Matches Drug MIDOSTAURIN	Interaction Type Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor	Sources TALC 140Clin (ALC 140Cl	iscarīnia (GC) TEND AKU MyCancerCenomeCi m OrugBank MyCancerCenomeCi m OrugBank MyCancerCenomeCi m OrugBank MyCancerCenomeCi eceGenom TdgCinicat eceGenom TdgCinicat eceGenom TdgCinicat eceGenom TdgCinicat mecinicatīnia GCI CIVIC mecinicatīnia Michaeli	1 TdgClinicaTrial Cherr sercerFaromeCinicaTrial (1 TdgClinicaTrial (1 TdgClinicaTrial (1 TdgClinicaTrial (1 GlastryFoundation	DrugBank TTD ClinicaTrial DrugBank clinicaTrial DrugBank clinicaTrial DrugBank clinicaTrial DrugBank gg/interactions DrugBank clinicaTrial DrugBank commons	24470005 1700706 24000706 14654505 058541007 14654505 105851007 14654505 1058500 14654505 1059500 14654505 1059500 14654505 1059500 14654505 1059500 14554517 1059500 14554517 1059501 2550014 1059502 2450100 1059502 155002 105000 2455010 1050000 155000 1050000 155000 1050000 155000 1050000 155000 1050000 155000 1050000 155000 1050000 155000 1050000 155000 1050000 155000 10500000 1550000 10500000 1550000 10500000 1550000 10500000 1550000 10500000 1550000 10500000 15500000 105000000 </td <td>10 9 7 7 7 7 7 7 7 7 7 7 7 4 1 39</td> <td>Preset Filters Unique Matches Search Term: FLT Search Term: FLT2 Search Term: AQP9 Download as TSV Unmatched Terms LOC100508755 EAKE1 Multiple Matches STK1 AURRB FIT3 COCK7 PULXNB2</td>	10 9 7 7 7 7 7 7 7 7 7 7 7 4 1 39	Preset Filters Unique Matches Search Term: FLT Search Term: FLT2 Search Term: AQP9 Download as TSV Unmatched Terms LOC100508755 EAKE1 Multiple Matches STK1 AURRB FIT3 COCK7 PULXNB2

Figure 3. The DGIdb interaction search interface. (A) A search field accepts drug or gene identifiers, depending on which tab is selected and provides autocompletion suggestions for search terms. (B) Preset options are provided to filter search results based on the attributes of mapped interactors. (C) Advanced filters allow the user to further filter based on source database, gene category or interaction type. (D) The interaction search results (Unique Matches) view shows results for search terms that were matched within the DGIdb. (E) The interaction search results (Ambiguous or Unmatched) view shows search terms that were either ambiguously matched or unmatched within the DGIdb. (F) Additional side panels provide a brief summary of unmatched and ambiguously matched terms.

have had success utilizing a community curation model. In an effort to enable community feedback to address the complexity of grouping and representing drug-gene interaction data, the DGIdb will be moved to a similar model. Expected changes include users creating login accounts, suggesting sources or claims for inclusion and verification that a source or claim has enough support to be included within the DGIdb. These changes will require significant code updates but will greatly increase the utility of the DGIdb.

AVAILABILITY

DGIdb is an open access database and web interface (www.dgidb.org) with open source code available on GitHub (https://github.com/griffithlab/dgi-db). We also provide data downloads for drug claims, gene claims, and interaction claims on the website in addition to a SQL data dump (http://dgidb.org/downloads). Information about the API and its endpoints can also be found on the website (http://dgidb.org/api).

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

FUNDING

National Human Genome Research Institute [R00HG007940 to M.G.]; National Cancer Institute [K22CA188163 to O.L.G., T32CA113275, F32CA206247 to A.H.W, T32CA113275 to K.C.C., U01CA209936]; National Institute of General Medical Sciences [5R25GM103757]. Funding for open access charge: National Institutes of Health [R00HG007940]. *Conflict of interest statement.* None declared.

REFERENCES

- Griffith,M., Griffith,O.L., Coffman,A.C., Weible,J.V., McMichael,J.F., Spies,N.C., Koval,J., Das,I., Callaway,M.B., Eldred,J.M. *et al.* (2013) DGIdb—mining the druggable genome. *Nat. Methods*, **10**, 1209–1210.
- Wagner,A.H., Coffman,A.C., Ainscough,B.J., Spies,N.C., Skidmore,Z.L., Campbell,K.M., Krysiak,K., Pan,D., McMichael,J.F., Eldred,J.M. *et al.* (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. *Nucleic Acids Res.*, 44, D1036–D1044.
- Brown,G.R., Hem,V., Katz,K.S., Ovetsky,M., Wallin,C., Ermolaeva,O., Tolstoy,I., Tatusova,T., Pruitt,K.D., Maglott,D.R. *et al.* (2015) Gene: a gene-centered information resource at NCBI. *Nucleic Acids Res.*, 43, D36–D42.
- Kim,S., Thiessen,P.A., Bolton,E.E., Chen,J., Fu,G., Gindulyte,A., Han,L., He,J., He,S., Shoemaker,B.A. *et al.* (2016) PubChem substance and compound databases. *Nucleic Acids Res.*, 44, D1202–D1213.
- Griffith,M., Spies,N.C., Krysiak,K., McMichael,J.F., Coffman,A.C., Danos,A.M., Ainscough,B.J., Ramirez,C.A., Rieke,D.T., Kujan,L. *et al.* (2017) CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. *Nat. Genet.*, 49, 170–174.
- Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J.E., Yaeger, R., Soumerai, T., Nissan, M.H. *et al.* (2017) OncoKB: a precision oncology knowledge base. *JCO Precis. Oncol.*, 1, doi:10.1200/PO.17.00011.

- Patterson,S.E., Liu,R., Statz,C.M., Durkin,D., Lakshminarayana,A. and Mockus,S.M. (2016) The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. *Hum. Genomics*, 10, 4.
- Finan, C., Gaulton, A., Kruger, F.A., Lumbers, R.T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R. *et al.* (2017) The druggable genome and support for target identification and validation in drug development. *Sci. Transl. Med.*, 9, eaag1166.
- Yeh, P., Chen, H., Andrews, J., Naser, R., Pao, W. and Horn, L. (2013) DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. *Clin. Cancer Res.*, 19, 1894–1901.
- Simon,G.R. and Somaiah,N. (2014) A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. *Clin. Lung Cancer*, 15, 21–51.
- Southan, C., Sharman, J.L., Benson, H.E., Faccenda, E., Pawson, A.J., Alexander, S.P.H., Buneman, O.P., Davenport, A.P., McGrath, J.C., Peters, J.A. et al. (2016) The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res., 44, D1054–D1068.
- Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V. et al. (2014) DrugBank 4.0: shedding new light on drug metabolism. *Nucleic Acids Res.*, 42, D1091–D1097.
- Gene Ontology Consortium (2015) Gene Ontology Consortium: going forward. *Nucleic Acids Res.*, 43, D1049–D1056.
- Bento,A.P., Gaulton,A., Hersey,A., Bellis,L.J., Chambers,J., Davies,M., Krüger,F.A., Light,Y., Mak,L., McGlinchey,S. *et al.* (2014) The ChEMBL bioactivity database: an update. *Nucleic Acids Res.*, **42**, D1083–D1090.
- 15. Edwards, A.M., Isserlin, R., Bader, G.D., Frye, S.V., Willson, T.M. and Yu, F.H. (2011) Too many roads not taken. *Nature*, **470**, 163–165.
- Kumar, R. D., Chang, L.-W., Ellis, M.J. and Bose, R. (2013) Prioritizing potentially druggable mutations with dGene: an annotation tool for cancer genome sequencing data. *PLoS One*, 8, e67980.
- 17. Hopkins, A.L. and Groom, C.R. (2002) The druggable genome. *Nat. Rev. Drug Discov.*, **1**, 727–730.
- Cheng, D.T., Mitchell, T.N., Zehir, A., Shah, R.H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z.Y., Won, H.H., Scott, S.N. *et al.* (2015) Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *J. Mol. Diagn.*, **17**, 251–264.
- Russ,A.P. and Lampel,S. (2005) The druggable genome: an update. *Drug Discov. Today*, **10**, 1607–1610.
 Mock,A., Murphy,S., Morris,J., Marass,F., Rosenfeld,N. and
- Mock,A., Murphy,S., Morris,J., Marass,F., Rosenfeld,N. and Massie,C. (2017) CVE: an R package for interactive variant prioritisation in precision oncology. *BMC Med. Genomics*, 10, 37.
- Thurnherr, T., Singer, F., Stekhoven, D.J. and Beerenwinkel, N. (2016) Genomic variant annotation workflow for clinical applications [version 2; referees: 2 approved]. *F1000Research*, 5, 1963.
- Hart,S.N., Moore,R.M., Zimmermann,M.T., Oliver,G.R., Egan,J.B., Bryce,A.H. and Kocher,J.-P.A. (2015) PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data. *PeerJ*, 3, e970.
- 23. Wu,C., Orozco,C., Boyer,J., Leglise,M., Goodale,J., Batalov,S., Hodge,C.L., Haase,J., Janes,J., Huss,J.W. *et al.* (2009) BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. *Genome Biol.*, **10**, R130.
- 24. Fisch,K.M., Meißner,T., Gioia,L., Ducom,J.-C., Carland,T.M., Loguercio,S. and Su,A.I. (2015) Omics Pipe: a community-based framework for reproducible multi-omics data analysis. *Bioinformatics*, **31**, 1724–1728.
- Paila, U., Chapman, B.A., Kirchner, R. and Quinlan, A.R. (2013) GEMINI: integrative exploration of genetic variation and genome annotations. *PLoS Comput. Biol.*, 9, e1003153.